Details for Patent: 9,393,256
Which drugs does patent 9,393,256 protect, and when does it expire?
Patent 9,393,256 protects HARVONI and is included in two NDAs.
Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-eight patent family members in forty-three countries.
Summary for Patent: 9,393,256
| Title: | Methods for treating HCV |
| Abstract: | This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions. |
| Inventor(s): | Adrian S. Ray, John O. Link, David W. Oldach, William E. Delaney, IV, Hongmei Mo, Cheng Yong Yang |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US13/875,252 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,393,256 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 9,393,256
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | 9,393,256*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | 9,393,256*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-002 | Aug 28, 2019 | RX | Yes | No | 9,393,256*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | 9,393,256*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,393,256
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 088580 | ⤷ Start Trial | |||
| Argentina | 089578 | ⤷ Start Trial | |||
| Australia | 2012308295 | ⤷ Start Trial | |||
| Australia | 2012332827 | ⤷ Start Trial | |||
| Australia | 2012346217 | ⤷ Start Trial | |||
| Brazil | 112014006324 | ⤷ Start Trial | |||
| Brazil | 112014010295 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
